Research Information System
Phoenix Medical Journal, vol.5, no.2, pp.94-100, 2023 (Peer-Reviewed Journal)
Objective: All over the world, a specific antiviral and immunomodulatory treatment method that can affect COVID-19 infection has not been found, and research is ongoing. Our goal is to share our clinical experience in patients receiving in patient treatment in our clinic. Materials and Methods: Patients whose symptoms were compatible with COVID-19 and whose microbiological findings and/or tomography findings were compatible between March 11 and May 31, 2020 were included in the study. Results: Among 180 patients included in the study; It was found that favipiravir treatment was added to 45 (25.0%) patients after HCQ treatment. A significant difference was found between treatment groups concerning; age, occupation, oxygen saturation, presence of diabetes mellitus, hypertansion and lung disease, and CT findings (p <0.05). Conclusion: In patient groups; Switching to favipiravir treatment and getting a response in patients aged 65 and over, with comorbidities, widespread CT involvement at admission, and Sat O2≤94 may be predictive in treatment selection.